![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection
|
|
|
Reported by Jules Levin
Conference on Retroviruses and Opportunistic Infections
Boston, MA, March 3-6, 2014
Everson GT,1 Thuluvath PJ,2 Lawitz E,3 Hassanein T,4 Rodriguez-Torres M,5
Hawkins T,6 Rustgi V,7 Hinestrosa F,8 Levin JM,9 Sims KD10
1University of Colorado Denver, Aurora, CO; 2Mercy Medical Center and University of Maryland School of Medicine, Baltimore, MD; 3The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 4Southern California Liver Centers, Coronado, CA; 5Fundacion de Investigacion, San Juan,
Puerto Rico; 6Southwest CARE Center, Santa Fe, NM; 7Metropolitan Research, Arlington, VA; 8Orlando Immunology Center, Orlando, FL; 9Dean Foundation for Health, Research and Education, Inc, Madison, WI; 10Bristol-Myers Squibb, Hopewell, NJ
![HCV1.gif](../images/030413/030414-7/HCV1.gif)
1 UNITY 1: http://www.clinicaltrials.gov/ct2/show/NCT01979939?term=daclatasvir+and+asunaprevir&rank=17
UNITY 2: http://www.clinicaltrials.gov/ct2/show/NCT01973049?term=daclatasvir+and+asunaprevir&rank=10
CROI webcast:
http://www.croiwebcasts.org/console/player/22172?mediaType=slideVideo&
![HCV2.gif](../images/030413/030414-7/HCV2.gif)
![HCV3.gif](../images/030413/030414-7/HCV3.gif)
![HCV4.gif](../images/030413/030414-7/HCV4.gif)
![HCV5.gif](../images/030413/030414-7/HCV5.gif)
![HCV6.gif](../images/030413/030414-7/HCV6.gif)
![HCV7.gif](../images/030413/030414-7/HCV7.gif)
![HCV8.gif](../images/030413/030414-7/HCV8.gif)
![HCV9.gif](../images/030413/030414-7/HCV9.gif)
![HCV10.gif](../images/030413/030414-7/HCV10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|